Ocular HSV-1: Preventing Recurrent Corneal Disease

眼部 HSV-1:预防复发性角膜疾病

基本信息

  • 批准号:
    6702922
  • 负责人:
  • 金额:
    $ 15.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-12-01 至 2007-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Recurrent herpes simplex virus type 1 (HSV-1) infection is a major cause of corneal blindness due to an infectious agent. Since over 80% of adults in the US harbor latent HSV, at this time a therapeutic treatment to prevent recurrent disease in latently infected individuals may be even more beneficial than a prophylactic treatment to prevent acquisition. Recently, a specific form of high intensity magnetic ion impulses (HIMII) appeared to prevent future HSV-1 recurrences in three of three individuals with a history of severe oral HSV-1 recurrences. Noninvasive HIMII can induce electrical current in neurons in vivo thus affecting their activity. Since neuronal HSV-1 latency is regulated at least in part by the neuron, it is logical that HIMII could affect the HSV-1 latency reactivation cycle. In addition to preventing clinical recurrences, the HIMII treatment also reduced anti-HSV serum antibody titers in all three subjects, from very high prior to treatment to below detectable levels one year after treatment. Since we recently showed that decreasing antibody titers are indicative of greatly reduced reactivation this finding argues against a simple placebo effect being responsible for the reduced clinical recurrences. We hypothesize that treatment with high intensity magnetic ion impulses (HIMII) can significantly decrease spontaneous reactivation in eyes of rabbits latently infected with HSV-I. Our Specific Aims include: (1)Confirm that HIMII treatment will significantly reduce spontaneous reactivation in the rabbit eye model. Virus shedding, recurrent eye disease, and anti-HSV-1 antibody titers will all be examined. (2)Test the hypothesis that HIMII treatment decreases spontaneous reactivation by decreasing the amount of latent HSV-1 in rabbit trigeminal ganglia. At various times after treatment the amount of latency will be determined using molecular techniques including in situ hybridization and in situ PCR to determine the relative number of latently infected neurons, and laser capture microdissection followed by real time PCR to determine the amount of latent virus in individual neurons. (3) Determine the optimal HIMII treatment regimen required for optimal suppression of HSV-1 spontaneous reactivation.
描述(由申请人提供):复发性单纯疱疹病毒1型(HSV-1)感染是由感染因子引起的角膜失明的主要原因。由于在美国超过80%的成年人潜伏着HSV,在这个时候,预防潜伏感染者复发的治疗可能比预防获得的预防性治疗更有益。最近,一种特殊形式的高强度磁离子脉冲(HIMII)似乎可以预防三名有严重口腔HSV-1复发史的个体中的三名未来HSV-1复发。非侵入性HIMII可以在体内诱导神经元电流从而影响其活动。由于神经元的HSV-1潜伏期至少部分由神经元调节,因此HIMII可能影响HSV-1潜伏期的再激活周期是合乎逻辑的。除了预防临床复发外,HIMII治疗还降低了所有三名受试者的抗hsv血清抗体滴度,从治疗前的很高水平降至治疗后一年的可检测水平以下。由于我们最近表明抗体滴度的降低表明再激活大大减少,这一发现反对简单的安慰剂效应是减少临床复发率的原因。我们假设高强度磁离子脉冲(HIMII)治疗可以显著降低潜伏感染hsv - 1的兔子眼睛的自发再激活。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN L WECHSLER其他文献

STEVEN L WECHSLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN L WECHSLER', 18)}}的其他基金

LAT-HVEM Interactions Effect HSV-1 Latency/Reactivation
LAT-HVEM 相互作用影响 HSV-1 潜伏期/重新激活
  • 批准号:
    8822657
  • 财政年份:
    2015
  • 资助金额:
    $ 15.15万
  • 项目类别:
HSV-1 LAT miRNAs: Neurovirulence, reactivation, mechanism
HSV-1 LAT miRNA:神经毒力、再激活、机制
  • 批准号:
    8730998
  • 财政年份:
    2013
  • 资助金额:
    $ 15.15万
  • 项目类别:
Corneal HSV-1: Newly discovered LAT miRNAs and latency
角膜 HSV-1:新发现的 LAT miRNA 和潜伏期
  • 批准号:
    8337866
  • 财政年份:
    2011
  • 资助金额:
    $ 15.15万
  • 项目类别:
Corneal HSV-1: Immunopathologic Mechanisms of HSK
角膜 HSV-1:HSK 的免疫病理学机制
  • 批准号:
    7755352
  • 财政年份:
    2008
  • 资助金额:
    $ 15.15万
  • 项目类别:
Corneal HSV-1: Immunopathologic Mechanisms of HSK
角膜 HSV-1:HSK 的免疫病理学机制
  • 批准号:
    7373354
  • 财政年份:
    2008
  • 资助金额:
    $ 15.15万
  • 项目类别:
Corneal HSV-1: Immunopathologic Mechanisms of HSK
角膜 HSV-1:HSK 的免疫病理学机制
  • 批准号:
    7539154
  • 财政年份:
    2008
  • 资助金额:
    $ 15.15万
  • 项目类别:
Corneal HSV-1: LAT Blocks Apoptosis in Rabbit TG
角膜 HSV-1:LAT 阻断兔 TG 细胞凋亡
  • 批准号:
    6326521
  • 财政年份:
    2001
  • 资助金额:
    $ 15.15万
  • 项目类别:
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency
角膜 HSV-1:LAT 的抗凋亡活性和潜伏期
  • 批准号:
    8466973
  • 财政年份:
    2001
  • 资助金额:
    $ 15.15万
  • 项目类别:
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency
角膜 HSV-1:LAT 的抗凋亡活性和潜伏期
  • 批准号:
    7490424
  • 财政年份:
    2001
  • 资助金额:
    $ 15.15万
  • 项目类别:
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency
角膜 HSV-1:LAT 的抗凋亡活性和潜伏期
  • 批准号:
    7892433
  • 财政年份:
    2001
  • 资助金额:
    $ 15.15万
  • 项目类别:

相似国自然基金

盲人脑网络可塑性的磁共振影像研究
  • 批准号:
    30900476
  • 批准年份:
    2009
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Prime editing for Crumbs homologue 1 (CRB1) Inherited Retinal Dystrophies
Crumbs 同源物 1 (CRB1) 遗传性视网膜营养不良的 Prime 编辑
  • 批准号:
    10636325
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Development of a novel depot delivery system for a glaucoma therapeutic
开发用于青光眼治疗的新型储库递送系统
  • 批准号:
    10699791
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Planning the VICTORY (VIsual ComplicaTions Of PrematuRitY) Study
规划 VICTORY(早产儿视觉并发症)研究
  • 批准号:
    10645471
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
In Vivo Function and Metabolism Evaluation of Glaucomatous RGCs by Two-Photon Scanning Laser Ophthalmology
双光子扫描激光眼科评价青光眼 RGC 的体内功能和代谢
  • 批准号:
    10660761
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Reversal of Ovarian Aging in Mice Through AAV-mediated Oocyte Reprogramming in vivo
通过 AAV 介导的体内卵母细胞重编程逆转小鼠卵巢衰老
  • 批准号:
    10723227
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Novel Polymer-antibody Conjugates as Long-acting Therapeutics for Ocular Diseases
新型聚合物-抗体缀合物作为眼部疾病的长效治疗药物
  • 批准号:
    10760186
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Genome Editing Therapy for Usher Syndrome Type 3
针对 3 型亚瑟综合症的基因组编辑疗法
  • 批准号:
    10759804
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Developing a novel disease-targeted anti-angiogenic therapy for CNV
开发针对 CNV 的新型疾病靶向抗血管生成疗法
  • 批准号:
    10726508
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Personalizing Circumpapillary Retinal Nerve Fiber Layer Thickness Norms for Glaucoma
个性化青光眼环视乳头视网膜神经纤维层厚度标准
  • 批准号:
    10728042
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Mechanisms of structural plasticity, client interactions, and co-aggregation of the lens ⍺-crystallins
晶状体α-晶状体的结构可塑性、客户相互作用和共聚集机制
  • 批准号:
    10709482
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了